Education
About Us
Working with TipRanks
Follow Us
Clal Biotechnology Industries Ltd (IL:CBI)
:CBI
Total Valuation
Clal Biotech has a market cap or net worth of 53.33M. The enterprise value is ―.
Market Cap53.33M
Enterprise Value―
Share Statistics
Clal Biotech has 156,846,200 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding156,846,200
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Clal Biotech’s return on equity (ROE) is -1.70 and return on invested capital (ROIC) is -9.47%.
Return on Equity (ROE)-1.70
Return on Assets (ROA)-0.92
Return on Invested Capital (ROIC)-9.47%
Return on Capital Employed (ROCE)-0.13
Revenue Per Employee2.97K
Profits Per Employee-514.21K
Employee Count146
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Clal Biotech is ―. Clal Biotech’s PEG ratio is -0.00855.
PE Ratio―
PS Ratio123.31
PB Ratio1.46
Price to Fair Value1.46
Price to FCF-8.24
Price to Operating Cash Flow-8.82
PEG Ratio-0.00855
Income Statement
In the last 12 months, Clal Biotech had revenue of 433.00K and earned -62.46M in profits. Earnings per share was -0.40.
Revenue433.00K
Gross Profit-183.00K
Operating Income-6.34M
Pretax Income-75.07M
Net Income-62.46M
EBITDA-6.34M
Earnings Per Share (EPS)-0.40
Cash Flow
In the last 12 months, operating cash flow was -5.42M and capital expenditures 0.00, giving a free cash flow of -5.42M billion.
Operating Cash Flow-5.42M
Free Cash Flow-5.42M
Free Cash Flow per Share-0.03
Dividends & Yields
Clal Biotech pays an annual dividend of 22.372, resulting in a dividend yield of ―
Dividend Per Share22.372
Dividend Yield―
Payout Ratio―
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.67
52-Week Price Change-12.23%
50-Day Moving Average34.66
200-Day Moving Average32.87
Relative Strength Index (RSI)42.17
Average Volume (3m)153.57K
Important Dates
Clal Biotech upcoming earnings date is ―, ―.
Last Earnings Date―
Next Earnings Date―
Ex-Dividend DateMar 29, 2021
Financial Position
Clal Biotech as a current ratio of 0.29, with Debt / Equity ratio of 78.41%
Current Ratio0.29
Quick Ratio0.29
Debt to Market Cap0.36
Net Debt to EBITDA-2.66
Interest Coverage Ratio-1.87
Taxes
In the past 12 months, Clal Biotech has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Clal Biotech EV to EBITDA ratio is -11.08, with an EV/FCF ratio of -10.85.
EV to Sales162.32
EV to EBITDA-11.08
EV to Free Cash Flow-10.85
EV to Operating Cash Flow-10.85
Balance Sheet
Clal Biotech has 1.61M in cash and marketable securities with 18.70M in debt, giving a net cash position of -17.10M billion.
Cash & Marketable Securities1.61M
Total Debt18.70M
Net Cash-17.10M
Net Cash Per Share-0.11
Tangible Book Value Per Share0.29
Margins
Gross margin is 0.00%, with operating margin of -1465.36%, and net profit margin of -14424.02%.
Gross Margin0.00%
Operating Margin-1465.36%
Pretax Margin-17338.11%
Net Profit Margin-14424.02%
EBITDA Margin-1465.36%
EBIT Margin-1530.72%
Analyst Forecast
The average price target for Clal Biotech is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―